Net income surged 115% year-over-year to $38.7 million.
Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.
New $300 million stock repurchase program authorized through 2029.
Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.
The Q1 2026 filing presents a dichotomy between accounting profitability and cash reality. On one hand, Envista is successfully growing its top line and expanding its operating margins, proving that its dental portfolio remains resilient and capable of absorbing fixed costs. The shift toward higher-margin segments and the strategic move into advanced aligner technology via the Versah acquisition provide a clear path for long-term growth. The company's ability to maintain gross margins at 55.3% despite tariff headwinds suggests a disciplined approach to supply chain and pricing management. However, the disconnect between net income and operating cash flow, paired with a heavy debt profile, introduces a layer of financial risk. Investors must weigh the impressive earnings acceleration against the reality of negative operating cash flow and the reliance on tax-driven bottom-line boosts. The overall impact of the filing is a company in a high-growth transition phase, where the success of its strategic investments and the management of its leverage will determine if it can transform this accounting momentum into sustainable, cash-backed compounding.